A Novel Therapy to Attenuate Acute Kidney Injury and Ischemic Allograft Damage after Allogenic Kidney Transplantation in Mice

摘要: Ischemia followed by reperfusion contributes to the initial damage allografts after kidney transplantation (ktx). In this study we tested hypothesis that a tetrapeptide EA-230 (AQGV), might improve survival and attenuate loss of function in mouse model renal ischemia/reperfusion injury (IRI) ischemia-induced delayed graft allogenic transplantation. IRI was induced male C57Bl/6N mice transient bilateral pedicle clamping for 35 min. Treatment with (20–50mg/kg twice daily i.p. four consecutive days) initiated 24 hours when acute (AKI) already established. The treatment resulted markedly improved dose dependent manner. Acute tubular two days diminished epithelial cell proliferation significantly enhanced treatment. Furthermore, CTGF up-regulation, marker post-ischemic fibrosis, at weeks less treated tissue. To learn more about these effects, measured blood flow (RBF) glomerular filtration rate (GFR) 28 IRI. both GFR RBF significantly. Next, recipients were (50 mg/kg) which allograft attenuating ischemic damage. conclusion, is novel promising therapeutic agent treating preventing IRI-induced post-transplant injury. Its beneficial effect associated perfusion regeneration cells.